Phaseline

Companies › Myricx Pharma

Myricx Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jul 2030.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MX006
Anti-B7-H3 antibody-drug conjugate
CD276Phase 1Advanced and/or Metastatic Solid Tumors Known to Express B7-H3Jul 2030

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07807241MX006Phase 1Advanced and/or Metastatic Solid Tumors Known to Express B7-H3OncologyJul 2030

Targets

CD276 (1)

Companies with the same targets

Beijing Biotech Hansoh BioMedical R&D Company Innolake Biopharm GSK

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.